Stockscreener 앱 받기
51.08
4.76%
2.32
시간 외 거래:
51.18
0.10
+0.20%
전일 마감가:
$48.76
열려 있는:
$50.7
하루 거래량:
23.13M
Relative Volume:
1.65
시가총액:
$173.17B
수익:
$45.44B
순이익/손실:
$16.18B
주가수익비율:
14.06
EPS:
3.634
순현금흐름:
$9.21B
1주 성능:
+6.00%
1개월 성능:
-26.65%
6개월 성능:
-40.89%
1년 성능:
-60.15%
1일 변동 폭
$50.11
$51.30
1주일 범위
$45.05
$51.30
52주 변동 폭
$45.05
$139.74
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
51.08 | 201.64B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade - The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedBuy/Sell Zone Confirmation Technical Analysis - Newser
Will a bounce in Novo Nordisk A s (b Shares) Adrhedged offer an exitNext Day Momentum Stock Forecasting Report - Newser
Applying sector rotation models to Novo Nordisk A s (b Shares) AdrhedgedPredictive AI Signals for Short-Term Trading - Newser
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Strategy with Real Time Monitoring - Newser
Does Novo Nordisk A s (b Shares) Adrhedged qualify in momentum factor screeningFree Market Surge Signal for Swing Traders - Newser
Published on: 2025-08-06 19:02:41 - Newser
Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty - Morningstar
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree AI Screening for Swing Trade Picks - Newser
Novo Nordisk lowers 2025 sales outlook, ADR price falls 21.83%. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR earnings beat by $0.04, revenue fell short of estimates - Investing.com
Novo Nordisk A/S Announces 7% Increase in Interim Dividend for 2025, Payment Dates Set - AInvest
Novo Nordisk ADR earnings beat by $11.56, revenue topped estimates - Investing.com India
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsFree Alpha Focused Technical Trade Signals - Newser
Chart based exit strategy for Novo Nordisk A s (b Shares) AdrhedgedVolume Confirmed Setup with Entry Confidence - Newser
Novo Nordisk A s (b Shares) Adrhedged’s volatility index tracking explainedMomentum Prediction Based on AI Backtesting - Newser
Novo faces shareholder lawsuit over guidance cut - MSN
Novo Nordisk ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Is Novo Nordisk A s (b Shares) Adrhedged forming a bottoming baseHistorical Stock Summary and ROI Review - Newser
Will earnings trigger a reversal in Novo Nordisk A s (b Shares) AdrhedgedMarket Correction Proof Stock Screening Analysis - Newser
What makes Novo Nordisk A s (b Shares) Adrhedged stock price move sharplyOver 200% growth - Jammu Links News
How many analysts rate Novo Nordisk A s (b Shares) Adrhedged as a “Buy”Superior investment outcomes - Jammu Links News
Published on: 2025-08-03 21:00:40 - Jammu Links News
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire Inc.
How volatile is Novo Nordisk A s (b Shares) Adrhedged stock compared to the marketSkyrocketing returns - Jammu Links News
How strong is Novo Nordisk A s (b Shares) Adrhedged company’s balance sheetOutstanding trading profits - Jammu Links News
Should I hold or sell Novo Nordisk A s (b Shares) Adrhedged stock in 2025Unlock real-time trading signals for gains - Jammu Links News
Is Novo Nordisk A s (b Shares) Adrhedged a growth stock or a value stockAchieve explosive financial results today - Jammu Links News
How does Novo Nordisk A s (b Shares) Adrhedged compare to its industry peersUnlock rapid growth potential in your portfolio - Jammu Links News
Published on: 2025-08-03 07:55:16 - Jammu Links News
What institutional investors are buying Novo Nordisk A s (b Shares) Adrhedged stockTremendous financial leverage - Jammu Links News
What analysts say about Novo Nordisk A s (b Shares) Adrhedged stockBuild a diversified portfolio for steady profits - Jammu Links News
How does Novo Nordisk A s (b Shares) Adrhedged generate profit in a changing economyUnlock powerful portfolio management tools - Jammu Links News
Kessler Topaz Meltzer & Check, LLP - GlobeNewswire Inc.
What catalysts could drive Novo Nordisk A s (b Shares) Adrhedged stock higher in 2025Top Growth Entry Points For Every Investor - Jammu Links News
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.63%
자본화:
|
볼륨(24시간):